Gastro-Retentive Drug Delivery Systems Outsourcing Market Revenue to Attain USD 3.86 Bn by 2035

Published: 19 Feb 2026

Author: Precedence Research

Share:

Gastro-Retentive Drug Delivery Systems Outsourcing Market Revenue and Trends 2026 to 2035

The global gastro-retentive drug delivery systems outsourcing market revenue was valued at USD 2.04 billion in 2025 and is expected to attain around USD 3.86 billion by 2035, growing at a CAGR of 6.58% during forecast period.The gastro-retentive drug delivery systems outsourcing market is experiencing unprecedented growth, driven by the rising demand for controlled-release oral formulations and cost-effective medications.

What Factors are Contributing to the Growth of the Gastro-Retentive Drug Delivery Systems Outsourcing Market?

The growing need for enhanced bioavailability & drug efficacy and the increasing prevalence of gastrointestinal disorders are expected to increase the demand for controlled-release treatments, accelerating the growth of the market. Several pharmaceutical companies are increasingly outsourcing manufacturing to Contract Development and Manufacturing Organizations (CDMOs) to reduce overhead costs, enhance operational flexibility, and speed up time-to-market. This also allows them to focus on their core competencies. The market’s growth is also primarily supported by the advanced formulation technologies that enable the development of more sophisticated and personalized gastro-retentive drug delivery systems (GRDDS).

Segment Insights

• By drug type, the biologics segment led the market while holding the largest share in 2025, owing to the growing demand for improved bioavailability of complex and unstable therapeutic molecules. Gastro-retentive systems assist in improving their retention time in the stomach, which supports better absorption and enhances therapeutic performance.
• By technology type, the floating drug delivery segment held the largest market share in 2025. Floating drug delivery systems (FDDS) are specifically designed to remain buoyant in the stomach, enabling drugs to remain longer in the gastric environment. They are frequently utilized for drugs that absorb better in acidic conditions or require extended release.
• By application, the anti-ulcer drugs segment registered its dominance over the global gastro-retentive drug delivery systems outsourcing market in 2025, owing to the increasing prevalence of gastrointestinal disorders like Gastroesophageal reflux disease (GERD), peptic ulcers, and H. pylori infections. Gastro-retentive drug delivery systems (GRDDS) significantly enhance the effectiveness of anti-ulcer medications and reduce the need for frequent dosing, thereby improving patient compliance.
• By route of administration, the oral segment accounted for the majority of the share in 2025, An oral dosage form provides regulated and sustained medication release over a long period of time. Oral dosage forms are non-invasive and easy to administer, making them the preferred route for gastric-related disease management. Gastro-retentive tablets/capsules can enhance the bioavailability of certain medications, mainly with low solubility.

Regional Insights

North America holds the dominant share in the global gastro-retentive drug delivery systems outsourcing market. The region has a strong presence of pharmaceutical companies and contract development and manufacturing organizations (CDMOs), which offer advanced formulation capabilities. The region’s leadership is driven by the growing demand for chronic disease management, a surge in healthcare spending, rising investments in specialized drug delivery technologies, and an increasing focus on improved patient adherence. The region has robust regulatory frameworks for safety and efficacy, which push manufacturers to rely on outsourcing partners for complex and sustained-release formulations. 

On the other hand, Asia Pacific is anticipated to grow at the fastest rate in the market during the forecast period. The fastest growth of the region is attributed to the increasing prevalence of gastrointestinal disorders, growing adoption of floating drug delivery systems, increasing need for enhanced drug bioavailability, and rapid expansion of CDMOs. In addition, the rising need for cost-effective, advanced, and regulatory-compliant drug delivery technologies is expected to boost the market’s growth across the region.

Gastro-Retentive Drug Delivery Systems Outsourcing Market Coverage

Recent Developments

• In September 2025, Evonik, a global specialty chemicals company, and Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, entered into a strategic collaboration to develop and market a novel lipid nanoparticle (LNP) platform for nucleic acid delivery. Through this collaboration, Evonik will expand its offering of formulation development services to customers with Ethris’ proprietary lipidoid nanoparticle (SNaP LNP) technology platform. (Source: https://www.evonik.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7715

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344